Advertisement

Drug Safety

, Volume 7, Issue 4, pp 292–303 | Cite as

A Reassessment of the Treatment of Salicylate Poisoning

  • Lidia Notarianni
Review Article Poisoning Management

Summary

The treatment of salicylate poisoning is ased on the prevention of further absorption, and enhancement of excretion of already absorbed drug. A variety of methods based on this rationale have been used over the years. One of the more popular and successful treatments has been forced alkaline diuresis to encourage excretion. This technique, however, is not without risk and has now been replaced with alkalinisation alone, which has been shown to be safer and equally successful. The use of activated charcoal as an acute adsorbing agent for drug still in the upper gastrointestinal tract is beneficial in minimising further absorption. A recent development in the use of activated charcoal is the administration of multiple doses which are believed to enhance elimination of absorbed drug. The charcoal adsorbs salicylate diffusing back into the gut from the coeliac and mesenteric blood vessels thereby effectively eliminating it — a form of ‘internal peritoneal dialysis’. Multiple-dose activated charcoal and alkalinisation are currently the most popular methods of treatment.

Keywords

Aspirin Salicylic Acid Salicylate Activate Charcoal Oral Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ali B, Kaur S. Mammalian tissue acetylsalicylic acid esterases. Identification, distribution and discrimination from other esterases. Journal of Pharmacology and Experimental Therapeutics 226: 589–594, 1983PubMedGoogle Scholar
  2. Alvan G, Bergman U, Gustafsson LL. High unbound fraction of salicylate in plasma during intoxication. British Journal of Clinical Pharmacology 11: 625–626, 1981PubMedCrossRefGoogle Scholar
  3. Anderson RJ, Potts DE, Gabow PA, Rumack BH, Schrier RW. Unrecognised adult salicylate intoxication. Annals of Internal Medicine 85: 745–748, 1976PubMedGoogle Scholar
  4. Atwood SJ. The laboratory in the diagnosis and management of acetaminophen and salicylate intoxications. Pediatric Clinics of North America 27: 871–879, 1980PubMedGoogle Scholar
  5. Barone JA, Raia JJ, Huang YC. Evaluation of the effects of multiple-dose activated charcoal on the absorption of orally administered salicylate in a simulated ingestion model. Annals of Emergency Medicine 17: 34–37, 1988PubMedCrossRefGoogle Scholar
  6. Berg KJ. Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics. European Journal of Clinical Pharmacology 12: 111–116, 1977PubMedCrossRefGoogle Scholar
  7. Bochner F, Graham GG, Cham E, Imhoff DM, Haavisto, TM. Salicylate metabolite kinetics after several salicylates. Clinical Pharmacology and Therapeutics 30: 266–275, 1981PubMedCrossRefGoogle Scholar
  8. Borga O, Odar-Cederlof I, Ringberger V, Norlin A. Protein binding of salicylate in uremic and normal plasma. Clinical Pharmacology and Therapeutics 20: 464–475, 1976PubMedGoogle Scholar
  9. Boldy D, Vale JA. Treatment of salicylate poisoning with repeated activated charcoal. British Medical Journal 292: 136, 1986PubMedCrossRefGoogle Scholar
  10. Burton BT, Bayer MJ, Barron L, Aitchison JP. Comparison of activated charcoal and gastric lavage in the prevention of aspirin absorption. Journal of Emergency Medicine 1: 411–416, 1984PubMedCrossRefGoogle Scholar
  11. Christensen LA, Schmidt EB. Perforated ulcer — a complication in acute salicylate intoxication. Acta Medica Scandanavica 222: 191–192, 1987CrossRefGoogle Scholar
  12. Chung DC, Murphy JE, Taylor TW. In-vivo comparison of the adsorption of ‘superactivated charcoal’ and fructose with activated charcoal. Journal of Toxicology and Clinical Toxicology 19: 219–224, 1982CrossRefGoogle Scholar
  13. Coppack SW, Higgens CS. Algorithm for modified alkaline diuresis in salicylate poisoning. British Medical Journal 289: 1452, 1984PubMedCrossRefGoogle Scholar
  14. Comstock EG, Boisaubin EV, Comstock BS, Faulkner TP. Assessment of the efficacy of activated charcoal following gastric lavage in acute drug emergencies. Journal of Toxicology and Clinical Toxicology 19: 149–165, 1982CrossRefGoogle Scholar
  15. Costello PB, Caruana, JA, Green, FA. The relative roles of hydrolases of the erythrocyte and other tissues in controlling aspirin survival in vivo. Arthritis and Rheumatism 27: 422–426, 1984PubMedCrossRefGoogle Scholar
  16. Danel V, Henry JA, Glucksman E. Activated charcoal, emesis, and gastric lavage in aspirin overdose. British Medical Journal, 296: 1507, 1988PubMedCrossRefGoogle Scholar
  17. Done AK. Salicylate intoxication: significance of measurements of salicylate in blood and cases of acute ingestion. Pediatrics 26: 800–807, 1960PubMedGoogle Scholar
  18. Eisen TF, Grbcich PA, Lacouture PG, Shannon MW, Woolf A. The adsorption of salicylates by a milk-charcoal mixture. Annals of Emergency Medicine 20: 143–146, 1991PubMedCrossRefGoogle Scholar
  19. Filippone GA, Fish SS, Lacouture PG, Scavone JM, Lovejoy FH, et al. Reversible absorption (desorption) of aspirin from activated charcoal. Archives of Internal Medicine 147: 1390–1392, 1987PubMedCrossRefGoogle Scholar
  20. Ferguson RK, Boutros AR. Death following self-poisoning with aspirin. Journal of the American Medical Association 213: 1186–1187, 1970PubMedCrossRefGoogle Scholar
  21. Gordon IJ, Bowler CS, Coakley J, Smith P. Algorithm for modified alkaline diuresis in salicylate poisoning. British Medical Journal 289: 1039–1040, 1984PubMedCrossRefGoogle Scholar
  22. Grbcich P, Lacouture P, Woolfe A. The feasibility of the administration of activated charcoal in the home. Veterinary and Human Toxicology 28: 471, 1987Google Scholar
  23. Harsch HH. Aspiration of activated charcoal. New England Journal of Medicine 314: 318, 1986PubMedGoogle Scholar
  24. Hillman RJ, Prescott LF. Treatment of salicylate poisoning with repeated oral charcoal. British Medical Journal 291: 1472, 1985PubMedCrossRefGoogle Scholar
  25. Kaufman FL, Dubansky AS. Darvon poisoning with delayed salicylism: a case report. Pediatrics 49: 610–611, 1972PubMedGoogle Scholar
  26. Keller RE, Schwab RA, Krenzelok EP. Contribution of sorbitol combined with activated charcoal in prevention of salicylate absorption. Annals of Emergency Medicine 19: 654–656, 1990PubMedCrossRefGoogle Scholar
  27. Kershaw RA, Mays DC, Bianchine JR, Gerber N. Disposition of aspirin and metabolites in the semen of man. Journal of Clinical Pharmacology 27: 304–309, 1987PubMedGoogle Scholar
  28. Kirshenbaum LA, Mathews SC, Sitar DS, Tenebein M. Does multiple-dose charcoal therapy enhance salicylate excretion. Archives of Internal Medicine 150: 1281–1283, 1990PubMedCrossRefGoogle Scholar
  29. Krenzelok EP, Heller MB. Effectiveness of commercially available aqueous activated charcoal products. Annals of Emergency Medicine 16: 1340–1343, 1987PubMedCrossRefGoogle Scholar
  30. Krenzelok EP, Keller RE, Stewart RD. Gastrointestinal transit time of cathartics combined with activated charcoal. Annals of Emergency Medicine 14: 1152–1155, 1985PubMedCrossRefGoogle Scholar
  31. Kwong TC, Laczin J, Baum J. Self-poisoning with enteric-coated aspirin. American Journal of Clinical Pathology 80: 888–890, 1983PubMedGoogle Scholar
  32. Lawson AAH, Proudfoot AT, Brown SS, MacDonald RH, Fraser AG, et al. Forced diuresis in the treatment of acute salicylate poisoning in adults. British Medical Journal 38: 31–48, 1969Google Scholar
  33. Levy G. Clinical pharmacokinetics of aspirin. Pediatrics 62 (Suppl.): 867–871, 1978PubMedGoogle Scholar
  34. Levy G. Pharmacokinetics of salicylate in man. Drug Metabolism Reviews 9: 3–19, 1979PubMedCrossRefGoogle Scholar
  35. Levy G. Gastrointestinal clearance of drugs with activated charcoal. New England Journal of Medicine 307: 676–678, 1982PubMedCrossRefGoogle Scholar
  36. Levy G, Sumner JY. Relationship between dose and apparent volume of distribution of salicylate in children. Pediatrics 54: 713–717, 1974PubMedGoogle Scholar
  37. Levy G, Vogel AW, Amsel LP. Capacity-limited salicylurate formation during prolonged administration of aspirin to healthy human subjects. Journal of Pharmaceutical Sciences 58: 503–504, 1969PubMedCrossRefGoogle Scholar
  38. Merck Index, 11th edition. Merck and Co., Rahway, New Jersey, 1989Google Scholar
  39. Mitchell I. ‘Therapeutic’ salicylate poisoning in children. British Medical Journal 1: 1081, 1979PubMedCrossRefGoogle Scholar
  40. Montagnac R, Schillinger F, Milcent T, Turret MM, Dinh A, et al. Extrarenal purification in severe salicylate poisoning in adults. Nephrologie 8: 55–57, 1987PubMedGoogle Scholar
  41. National Poisons Information Service Monitoring Group. Analgesic poisoning: a multi-centre, prospective survey. Human Toxicology 1: 7–23, 1981CrossRefGoogle Scholar
  42. Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clinical Pharmacokinetics 10: 164–167, 1985PubMedCrossRefGoogle Scholar
  43. Neuvonen PJ. Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clinical Pharmacokinetics 7: 465–489, 1982PubMedCrossRefGoogle Scholar
  44. Neuvonen PJ, Elfving SM, Elonen E. Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. European Journal of Clinical Pharmacology 13: 213–218, 1978PubMedCrossRefGoogle Scholar
  45. Neuvonen PJ, Olkkola K. Oral activated charcoal in the treatment of intoxications: role of single and repeated doses. Medical Toxicology 3: 33–58, 1988PubMedGoogle Scholar
  46. Niyogi SK, Rieders F. Salicylate poisoning: differences in tissue levels and distribution between children and adults. European Journal of Toxicology 2: 234–238, 1969Google Scholar
  47. Notarianni LJ, Ogunbona A, Oldham HG, Patel DK, Bennett PN, et al. Glycine conjugation of salicylic acid after aspirin overdose. British Journal of Clinical Pharmacology 15: 587P, 1983Google Scholar
  48. Park G, Spector R, Goldberg M, Johnson GF. Expanded role of charcoal therapy in the poisoned and overdosed patient. Archives of Internal Medicine 146: 969–973, 1986PubMedCrossRefGoogle Scholar
  49. Patel DK. Metabolism of aspirin after therapeutic and toxic doses. Ph.D. Thesis, University of Bath, England, 1985Google Scholar
  50. Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN. Metabolism of aspirin after therapeutic and toxic doses. Human and Experimental Toxicology 9: 131–136, 1990aPubMedCrossRefGoogle Scholar
  51. Patel DK, Ogunbona A, Notarianni LJ, Bennett PN. Depletion of plasma glycine and effect of glycine by mouth on salicylate metabolism during aspirin overdose. Human and Experimental Toxicology 9: 389–395, 1990bPubMedCrossRefGoogle Scholar
  52. Pond SM. Role of repeated oral doses of activated charcoal in clinical toxicology. Medical Toxicology 1: 3–11, 1986PubMedGoogle Scholar
  53. Prescott LF, Balali-Mood M, Critchley JAJH, Johnstone AF, Proudfoot AT. Diuresis or urinary alkalinisation for salicylate poisoning? British Medical Journal 285: 1383–1386, 1982PubMedCrossRefGoogle Scholar
  54. Riggs BS, Kulig K, Rumack BH. Current status of aspirin and acetaminophen intoxication. Pediatric Annals 16: 886–898, 1987PubMedGoogle Scholar
  55. Robins JB, Turnbull JA, Robertson C. Gastric perforation after acute aspirin overdose. Human Toxicology 4: 527–528, 1985PubMedCrossRefGoogle Scholar
  56. Rowland M, Riegelman S. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man. Journal of Pharmaceutical Sciences 57: 1313–1319, 1968CrossRefGoogle Scholar
  57. Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. Journal of Pharmaceutical Sciences 61: 379, 1972PubMedCrossRefGoogle Scholar
  58. Snodgrass W, Rumack BH. Salicylate toxicity following therapeutic doses in young children. Clinical Toxicology 18: 247–259, 1981PubMedCrossRefGoogle Scholar
  59. Spenney, JG. Acetylsalicylic acid hydrolase of gastric mucosa. American Journal of Physiology 234: E606–E610, 1978PubMedGoogle Scholar
  60. Temple AR, George DJ, Done AK, Thompson AJ. Salicylate poisoning complicated by fluid retention. Clinical Toxicology 9: 61–68, 1976PubMedCrossRefGoogle Scholar
  61. Todd PJ, Sills JA, Harris F, Cowen JM. Problems associated with overdoses of sustained-release aspirin. Lancet 2: 777, 1981CrossRefGoogle Scholar
  62. Tweedale MG. Salicylate and pulmonary edema. Annals of Internal Medicine 81: 710–711, 1974Google Scholar
  63. Vertrees JE, McWilliams BC, Kelly HW. Repeated oral administration of activated charcoal for treating aspirin overdose in young children. Pediatrics 85: 594–597, 1990PubMedGoogle Scholar
  64. Watson WA, Cremer KF, Chapman JA. Gastrointestinal obstruction associated with multiple-dose charcoal. Journal of Emergency Medicine 4: 401–407, 1986PubMedCrossRefGoogle Scholar
  65. Wortzman DJ, Grunfield A. Delayed absorption following enteric-coated aspirin overdose. Annals of Emergency Medicine 16: 434–436, 1987PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Lidia Notarianni
    • 1
  1. 1.School of Pharmacy and PharmacologyUniversity of BathClaverton Down, BathEngland

Personalised recommendations